Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer

OBJECTIVE: The purpose of this study was to employ dual tracers 16α-[18F]fluoro-17β-estradiol ((18)F-FES) and [18F]fluorodeoxyglucose ((18)F-FDG) as imaging biomarkers in predicting progression-free survival (PFS) in ER-positive metastatic breast cancer (MBC) patients receiving fulvestrant therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Cheng, Xu, Xiaoping, Yuan, Huiyu, Zhang, Yongping, Zhang, Yingjian, Song, Shaoli, Yang, Zhongyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673439/
https://www.ncbi.nlm.nih.gov/pubmed/33251143
http://dx.doi.org/10.3389/fonc.2020.580277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673439/
https://www.ncbi.nlm.nih.gov/pubmed/33251143
http://dx.doi.org/10.3389/fonc.2020.580277

Ejemplares similares